Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection.
A number of subunit-based vaccine candidates have recently begun to erode the exclusive position of Mycobacterium bovis bacillus Calmette-Guérin (BCG), which gives unpredictable and highly variable protection against tuberculosis. In this paper we investigated the protective capacity of the 19,000 MW and 38,000 MW glyco-lipoproteins of M. tuberculosis expressed by recombinant vaccinia viruses in a mouse Mycobacterium tuberculosis infection model. Both proteins were expressed at high levels by recombinant vaccinia-infected cells. In addition, two inoculations of C57B1/6 mice with either recombinant vaccinia virus significantly reduced the bacterial counts in the lungs of M. tuberculosis H37Rv-infected mice, when compared with the group infected with control virus. This is the first report of protection against tuberculous infection using recombinant vaccinia viruses with results that suggest that secreted glyco-lipoproteins in conjunction with the vaccinia vector represent suitable candidates for further vaccine-related studies.
Zhu
X
X
MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK.
Venkataprasad
N
N
Ivanyi
J
J
Vordermeier
H M
HM
D000818:Animals; D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology; D001426:Bacterial Proteins / Q000737:chemistry / Q000276:immunology; D015153:Blotting, Western; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D008970:Molecular Weight; D009169:Mycobacterium tuberculosis / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*; D014614:Vaccines, Synthetic; D014616:Vaccinia virus
D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D014614:Vaccines, Synthetic